Clinical trial

Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g

NCT01480219

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2011-08-01

PhaseN/A

Study timeline

Study start (unknown)2011-08-01Date precision: month

Registry last updated2013-03-11

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-Melanoma Skin Carcinomaunresolved

Interventions

voriconazole (Vfend)DRUG

no voriconazole (Vfend)OTHER

Sponsors & collaborators

Pfizerlead sponsor

University of Southern Californiacollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01480219 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.